Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB, often referred to as Sobi, is a biopharmaceutical company that specializes in rare disease therapies. Its core mission is to develop and commercialize innovative treatments that address serious unmet medical needs. The company's portfolio primarily focuses on hematology and immunology, serving patients with rare disorders such as hemophilia, hereditary angioedema, and other immunological diseases. Sobi's commitment to scientific research and patient care positions it as a leader in the orphan drug sector, where it plays a crucial role in improving the quality of life for individuals affected by rare diseases. By extending the lifecycle of existing treatments and pioneering new therapies, Sobi has carved out a vital niche in the healthcare industry. Through its strategic partnerships and global distribution networks, the company ensures that its life-changing products reach patients worldwide. Based in Stockholm, Sweden, Swedish Orphan Biovitrum AB stands as a testament to the impact dedicated research and focused therapeutics can have within the specialized healthcare market.